Latest News
Oct 15, 2025
Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone CapitalInitial Conversion Price of $5.00 Per Share Representing a 280% Premium Over the Company’s Recent Closing Price of $1.78 MELBOURNE, Australia, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. ("Propanc" or…
View All Press Releases